

Литература

1. Яхно Н.Н., Боголепова А.Н., Захаров В.В. Нарушение когнитивных функций. В кн.: Неврология: национальное руководство. Под ред. Е.И. Гусева, А.Н. Коновалова, В.И. Скворцовой. 2-е изд., перераб и доп. М.: ГЭОТАР-Медиа, 2017: 244-258.
2. Деменция. Информационный бюллетень ВОЗ. Декабрь 2017 г.
3. Sorbi S, Hort J, Erkinjuntti T et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. *European Journal of Neurology* 2012, 19: 1159-1179.
4. World Health Organization. Dementia: A Public Health Priority. Geneva: World Health Organization; 2012. http://apps.who.int/iris/bitstream/10665/75263/1/9789241564458_eng.pdf Accessed March 21, 2018.
5. Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer Report 2014. Dementia and risk reduction: an analysis of protective and modifiable risk factors. London: Alzheimer's Disease International, 2014. <http://www.alz.co.uk/research/WorldAlzheimerReport2014.pdf>.
6. Fitzpatrick AL et al. Survival following dementia onset: Alzheimer's disease and vascular dementia. *Journal of the Neurological Sciences*, 2005, 229-230: 43-49.
7. Prince M, Wimo A, Guerchet M, Ali GC, Wu Yutzu, Prina M. World Alzheimer Report 2015. The global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer's Disease International, 2015.
8. Petersen RS, Touchon J. Consensus on mild cognitive impairment. *Research and practice in Alzheimer's disease, E.A.D.C. A.D.C.S. Joint meeting*. 2005; 10: 24-32.
9. Яхно Н.Н., Захаров В.В., Локшина А.Б., Коберская Н.Н., Мхитарян Э.А. Деменции. Руководство для врачей. М., 2011.
10. Alzheimer's Association. 2017 Alzheimer's Disease Facts and Figures. *Alzheimers Dement.* 2017; 13: 325-373.

11. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. *Psychological medicine*. 1989; 19(4): 1015-1022.
12. Эндокринология: Национальное руководство. 2-е изд. Под ред. акад. РАН И.И. Дедова, акад. РАН Г.А. Мельниченко. М., 2016.
13. Боголепова А.Н. Приверженность антидементной терапии. *Фарматека*. 2014; 9: 50-54.
14. Haider B, Schmidt R, Schweiger C, Forstner T, Labek A, Lampl C. Medication Adherence in Patients With Dementia: An Austrian Cohort Study. *Alzheimer Dis Assoc Disord*. 2014 Apr-Jun; 28(2): 128-133. doi: 10.1097/WAD.0000000000000006.
15. Brewer L, Bennett K, McGreevy C, Williams D. A population-based study of dosing and persistence with anti-dementia medications. *Eur J Clin Pharmacol*. 2013; 69(7): 1467-1475.
16. Gadzhanova S, Roughead L, Mackson J. Anticholinesterase duration in the Australian veteran population. *Aust N Z J Psychiatry*. 2010; 44(5): 469-474.
17. Стулин И.Д., Солонский Д.С., Труханов С.А. Ультразвуковые методы исследования. В кн.: Неврология: национальное руководство. Под ред. Е.И. Гусева, А.Н. Коновалова, В.И. Скворцовой. 2-е изд., перераб и доп. М.: ГЭОТАР-Медиа, 2017: 60-82.
18. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. *Journal of psychiatric research*. 1975; 12(3): 189-198.
19. Левин О.С. Алгоритмы диагностики и лечения деменции. 2012.
20. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. *Neurology*. 2000; 55: 1621-1626.
21. Lovenstone S, Gauthier S. Management of dementia. London: Martin Dunitz, 2001.
22. Scharre DW et al. Digitally translated Self-Administered Gerocognitive Examination (eSAGE): relationship with its validated paper version, neuropsychological evaluations, and clinical assessments. *Alzheimer's Research & Therapy*. 2017; 9: 44.

23. <https://memini.ru/glossary/109>.
24. Morris JC. The clinical dementia rating (CDR). Current version and scoring rules. *Neurology*. 1993; 43: 2412-2413.
25. Kratz T. The diagnosis and treatment of behavioral disorders in dementia. *Dtsch Arztebl Int*. 2017; 114: 447-454. DOI: 10.3238/arztebl.2017.0447.
26. Колыхалов И.В. Лечение поведенческих и психотических симптомов деменции во внебольничных условиях: Методические рекомендации. М., 2012.
27. Cummings JL, Mega M, Gray K et al. The neuropsychiatric inventory: comprehensive assessment to psychopathology in dementia. *Neurology*. 1994; 44: 2308-2314.
28. Гусев Е.И., Боголепова А.Н. Депрессивные расстройства у пациентов с цереброваскулярными заболеваниями. М., 2014.
29. Боголепова А.Н., Коваленко Е.А., Махнович Е.В. Современные подходы к терапии тревожных расстройств у пациентов пожилого возраста. *Медицинский совет. Неврология/Ревматология*. 2017, 60-65.
30. Боголепова А.Н. Нарушения сна и болезнь Альцгеймера. *Неврология, нейропсихиатрия, психосоматика*. 2018; 10(1): 74-77.
31. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H et al. The role of biomarkers in clinical trials for Alzheimer disease. *AlzheimerDisAssocDisord*. 2006; 20: 6-15.
32. Forlenza OV et al. Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2015; 1: 455-463.
33. Докукина Т.В., Полещук Н.Н., Рубаник Л.В., Асташонок А.Н., Пинчук А.С., Королевич П.П., Махров М.В. Метод клинико-лабораторной диагностики болезни Альцгеймера. Минск, 2015. <http://med.by/methods/pdf/223-1215.pdf>.
34. Martinez-Ramirez S, Greenberg SM, Viswanathan A. Cerebral microbleeds: overview and implications in cognitive impairment. *Alzheimers Res Ther*. 2014; 6(3): 33.
35. Парфенов В.А. Дисциркуляторная энцефалопатия и сосудистые когнитивные расстройства. М.: ИМА-пресс, 2017.

36. Pasi M, Poggesi A, Pantoni L. The use of CT in dementia. *International Psychogeriatrics* 2011, 23(Suppl 2): 6-12.
37. Wattjes MP. Structural MRI *International Psychogeriatrics*. 2011; 23 (Suppl 2): 13-24. doi: 10.1017/S1041610211000913.
38. Filippi M. EFNS task force: the use of neuroimaging in the diagnosis of Dementia. *European Journal of Neurology*. 2012; 19: 1487-1511.
39. Одинак М.М., Емелин А.Ю., Труфанов А.Г. Позитронная эмиссионная томография. В кн.: Неврология: Национальное руководство. Под ред. Е.И. Гусева, А.Н. Коновалова, В.И. Скворцовой. 2-е изд., перераб и доп. М.: ГЭОТАР-Медиа, 2017: 55-58.
40. Herholz K. Perfusion SPECT and FDG-PET. *International Psychogeriatrics*. 2011; 23(Suppl 2): 25-31. doi: 10.1017/S1041610211000937.
41. Villemagne VL, Rowe ChC. Amyloid imaging. *International Psychogeriatrics*. 2011; 23(Suppl 2): 41-49. doi: 10.1017/S1041610211000895.
42. Livingston G, Sommerlad A, Orgeta V et al. Dementia prevention, intervention, and care. *The Lancet Commissions*. Published Online July 20, 2017 [http://dx.doi.org/10.1016/S0140-6736\(17\)31363-6](http://dx.doi.org/10.1016/S0140-6736(17)31363-6).
43. Valenzuela MJ, Sachdev P. Brain reserve and dementia: a systematic review. *Psychol Med*. 2006; 36: 441-454.
44. Sofi F, Valecchi D, Bacci D et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. *J Intern Med*. 2011; 269: 107-117.
45. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. *Psychol Med*. 2009; 39: 3-11.
46. Lenoir H, Dufouil C, Auriacombe S, Lacombe JM, Dartigues JF, Ritchie K, Tzourio C. Depression history, depressive symptoms, and incident dementia: the 3C Study. *J Alzheimers Dis*. 2011; 26(1): 27-38. doi: 10.3233/JAD-2011-101614.
47. Bubu OM, Brannick M, Mortimer J, Umasabor-Bubu O, Sebastião YV, Wen Y, Schwartz S, Borenstein AR, Wu Y, Morgan D, Anderson WM. Sleep,

Cognitive impairment, and Alzheimer's disease: A Systematic Review and Meta-Analysis. *Sleep*. 2017 Jan 1; 40(1). doi: 10.1093/sleep/zsw032.

48. Рекомендации по лечению артериальной гипертензии Американской кардиологической ассоциации (АНА). 2017.

49. Клинические рекомендации МЗ РФ «Артериальная гипертензия у взрослых». КР62, 2016.

50. Рекомендации Национального общества по изучению атеросклероза (НОА), VI пересмотр. 2017.

51. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. *Cochrane Database Syst Rev*. 2016a; (1): CD003160.

52. Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. *Lancet Neurology*. 2006; 5(1): 64-74.

53. Akomolafe A, Beiser A, Meigs JB et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. *Arch Neurol*. 2006; 63(11): 1551-1555.

54. Боголепова А.Н. Болезнь Альцгеймера и сахарный диабет. *Медицинский Совет*, 2015; 18: 36-41.

55. Jacobs V, Woller SC, Stevens SM et al. Percent time with a supratherapeutic INR in atrial fibrillation patients also using an antiplatelet agent is associated with long-term risk of dementia. *J Cardiovasc Electrophysiol*. 2015; 26: 1180-1186.

56. World Health Organization. *Dementia: A Public Health Priority*. Geneva: World Health Organization; 2012. http://apps.who.int/iris/bitstream/10665/75263/1/9789241564458_eng.pdf Accessed March 21, 2018.

57. Боголепова А.Н. Осведомленность населения РФ о проблеме деменции. *Журнал неврологии и психиатрии им. С.С. Корсакова*. 2015; 6: 97-103.

58. Petersen RC et al. Practice guideline update summary: Mild cognitive impairment. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology* 2018; 90 (3): 126-135. doi:10.1212/WNL.0000000000004826. www.pro.memini.ru.

59. Яхно Н.Н., Захаров В.В. Применение винпотропила при дисциркуляторной энцефалопатии с недементными когнитивными нарушениями. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010; 110(11): 13-16.
60. Боголепова А.Н., Бурд С.Г., Фрис Я.Е. Возможности использования комбинированной терапии у больных с хронической ишемией мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018; 118(8): 33-37.
61. Waldemar G, Dubois B, Emre M et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007; 14: 1-26.
62. Herrmann N, Lanctot KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013; 5(Suppl 1): S5.
63. Hansen RA, Gartlehner G, Webb AP. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. Clin Interv Aging. 2008; 3(2): 211-225.
64. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev. 2004; 1: CD004395.
65. Rabins PV, Blacker ChD, Rovner BW, Rummans T, Schneider LS, Tariot PN, Blass DM. Practice guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition. Work group on Alzheimer`s disesse and other dementias. 2007.
66. Ilhan Algin D, Dagli Atalay S, Ozkan S, Ozbabalik Adapinar D, Ak Sivrioz I. Memantine improves semantic memory in patients with amnesic mild cognitive impairment: A single-photon emission computed tomography study. Journal of International Medical Research. 2017 Dec; 45(6): 2053-2064.
67. Pelton GH, Harper OL, Roose SP et al. Combined treatment with memantine/escitalopram for older depressed patients with cognitive impairment: a pilot study. Int J Geriatr Psychiatry. 2015; 11: 4375.

68. Zhang N, Wei Ch, Du H et al. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients *Dement Geriatr Cogn Disord*. 2015; 40: 85-93.
69. Kishi T, Matsunaga S, Oya K, Ikuta T, Iwata N. Protection against brain atrophy by anti-dementia medication in mild cognitive impairment and Alzheimer's disease: meta-analysis of longitudinal randomized placebo-controlled trials. *Int J Neuropsychopharmacol*. 2015; 18(12): yv070.
70. Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. *PLoS One*. 2015; 10(4): e0123289.
71. Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. *Int J Neuropsychopharmacol*. 2014; 18(5): yu115.
72. Jiang J, Jiang H. Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials. *NeuroSci. Neurol Sci*. 2015 Sep; 36(9): 1633-1641. doi: 10.1007/s10072-015-2221-2.
73. McShane R, AreosaSastre A, Minakaran N. Memantine for dementia. *The Cochrane database of systematic reviews*. 2006; (2): CD003154.
74. Kishia T, Matsunaga Sh et al. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. *Journal of Alzheimer's Disease*. 2017; 60: 401-425.
75. Schmidt R, Hofer E, Bouwman FH et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesteraseinhibitors and memantine in moderate to severe Alzheimer's disease. *European Journal of Neurology*. 2015; 22: 889-898.
76. Kishi T, Matsunaga Sh, Iwata N. The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis. *Neuropsychiatric Disease and Treatment*. 2017; 13: 1909-1.